Jefferies Maintains Buy for Precision BioSciences (DTIL) March 13, 2026

Jefferies maintained a Buy rating on Precision BioSciences, Inc. (DTIL) on March 13, 2026. The firm lowered its price target to $19 while saying the near-term setup remains attractive. The DTIL analyst rating note is the primary analyst action this week and gives investors a clear short-term signal. We review the Jefferies view, the price target change, and what this maintained Buy means for holders and potential buyers.

DTIL analyst rating: Jefferies maintains Buy and lowers PT to $19

On March 13, 2026, Jefferies kept a Buy rating on Precision BioSciences (DTIL) and cut the price target to $19. Jefferies called the near-term setup attractive while trimming expectations. The note was reported by StreetInsider and flagged the PT change as the main UPDATE for investors. Read the Jefferies note source.

What Jefferies said about Precision BioSciences and the near-term setup

Jefferies lowered its target but left the rating at Buy, signaling confidence in the medium-term story. The firm highlighted near-term catalysts as supportive despite the PT cut. Jefferies’ language suggests they expect event-driven upside even as they adjust modeled outcomes.

How the DTIL analyst rating change links to recent stock moves

The note coincided with a reported 11.11% price change of $0.63 since the referenced point. Precision BioSciences has a market cap of $80,817,370, which frames how analyst moves affect liquidity and volatility. A maintained Buy with a lower PT often tempers upside while still endorsing accumulation.

Analyst coverage history and where this note fits

This March 13, 2026 Jefferies note is the sole rating change reported in our feed for DTIL this cycle. Coverage has been selective, and Jefferies remains a visible voice for this stock. No other major firms issued upgrades or downgrades in this latest round.

What the rating means for investors and portfolio impact

A maintained Buy from Jefferies signals continued conviction but a lower price target reduces implied near-term upside. Investors should weigh the $19 PT against entry price and time horizon. Meyka AI rates DTIL with a grade of B. This grade factors S&P 500 comparisons, sector performance, growth metrics, and analyst consensus. These grades are not guarantees and are not financial advice.

Market context, next catalysts, and how we track DTIL analyst rating

Key upcoming drivers may include clinical updates, partnership news, and quarterly filings. We monitor those events because Jefferies cited near-term catalysts. For real-time tracking use our platform page for DTIL on Meyka Meyka DTIL page. For broader analyst coverage context see recent market analyst summaries source.

Final Thoughts

Jefferies’ March 13, 2026 note left the rating at Buy but trimmed the price target to $19, signaling cautious optimism for Precision BioSciences (DTIL). The maintained Buy keeps the stock on a positive analyst list while the lower PT narrows expected near-term gains. Investors should compare the $19 target to their entry price and risk tolerance. With a market cap of $80,817,370, DTIL can move quickly on news and analyst notes. Meyka AI rates DTIL with a grade of B. That grade blends S&P 500 benchmarking, sector performance, financial growth, key metrics, and analyst consensus. Use the Jefferies view with your own timeline and follow upcoming catalysts that Jefferies flagged as supportive.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.